ECSP077978A - Anticuerpos monoclonales anti-trkb y usos de los mismos - Google Patents
Anticuerpos monoclonales anti-trkb y usos de los mismosInfo
- Publication number
- ECSP077978A ECSP077978A EC2007007978A ECSP077978A ECSP077978A EC SP077978 A ECSP077978 A EC SP077978A EC 2007007978 A EC2007007978 A EC 2007007978A EC SP077978 A ECSP077978 A EC SP077978A EC SP077978 A ECSP077978 A EC SP077978A
- Authority
- EC
- Ecuador
- Prior art keywords
- antibodies
- trkb
- human
- monoclonal antibodies
- same
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
Abstract
La presente invención proporciona anticuerpos monoclonales para el TrkB humano. En algunas modalidades los anticuerpos de la invención se unen y activan el TrkB humano. En algunas modalidades de la invención los anticuerpos son selectivos para el TrkB humano ya que no se unen (ni activan) el TrkA humano o el TrkC humano. En algunas modalidades los anticuerpos monoclonales presentan reactividad cruzada con TrkB murina. Versiones humanizadas o figuradas de los anticuerpos también son consideradas. Las composiciones farmacéuticas que comprenden los anticuerpos de la invención son proporcionados como métodos para preparar los anticuerpos y métodos de la invención para utilizar los mismos con propósitos de tratamiento, detección y purificación.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68770505P | 2005-06-06 | 2005-06-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP077978A true ECSP077978A (es) | 2008-01-23 |
Family
ID=37400063
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2007007978A ECSP077978A (es) | 2005-06-06 | 2007-12-03 | Anticuerpos monoclonales anti-trkb y usos de los mismos |
Country Status (21)
Country | Link |
---|---|
US (2) | US7750122B2 (es) |
EP (2) | EP1891114A2 (es) |
JP (1) | JP2008545781A (es) |
KR (1) | KR20080032070A (es) |
CN (1) | CN101273064A (es) |
AR (1) | AR053401A1 (es) |
AU (1) | AU2006255101A1 (es) |
BR (1) | BRPI0610938A2 (es) |
CA (1) | CA2610771A1 (es) |
EC (1) | ECSP077978A (es) |
GT (1) | GT200600240A (es) |
IL (1) | IL187710A0 (es) |
MX (1) | MX2007015292A (es) |
NI (1) | NI200700315A (es) |
NO (1) | NO20076157L (es) |
NZ (1) | NZ563941A (es) |
PA (1) | PA8678401A1 (es) |
PE (1) | PE20070183A1 (es) |
RU (1) | RU2007144678A (es) |
TW (1) | TW200722437A (es) |
WO (1) | WO2006133164A2 (es) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
EP2248899B8 (en) | 2003-03-19 | 2015-07-15 | Biogen MA Inc. | NOGO receptor binding protein |
WO2006002437A2 (en) | 2004-06-24 | 2006-01-05 | Biogen Idec Ma Inc. | Treatment of conditions involving demyelination |
AU2006269458B2 (en) | 2005-07-08 | 2012-11-08 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
WO2007064972A2 (en) | 2005-11-30 | 2007-06-07 | Abbott Laboratories | Monoclonal antibodies against amyloid beta protein and uses thereof |
ES2524984T3 (es) | 2005-11-30 | 2014-12-16 | Abbvie Inc. | Anticuerpos anti-globulómero a?, porciones de unión a antígeno de estos, hibridomas correspondientes, ácidos nucleicos, vectores, células huésped, métodos para producir dichos anticuerpos, composiciones que comprenden dichos anticuerpos, usos de dichos anticuerpos, y métodos para usar dichos anticuerpos |
CA2669205A1 (en) * | 2006-11-09 | 2008-05-15 | Irm Llc | Agonist trkb antibodies and uses thereof |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
EP2114436A1 (en) * | 2006-12-20 | 2009-11-11 | Rinat Neuroscience Corp. | Trkb agonists for treating autoimmune disorders |
US8895004B2 (en) | 2007-02-27 | 2014-11-25 | AbbVie Deutschland GmbH & Co. KG | Method for the treatment of amyloidoses |
WO2009048605A1 (en) * | 2007-10-11 | 2009-04-16 | Biogen Idec Ma Inc. | Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell, survival via administration of lingo-1 antagonists and trkb agonists |
MX2010004494A (es) * | 2007-10-23 | 2010-08-30 | Novartis Ag | Uso de anticuerpos de trkb para el tratamiento de trastornos respiratorios. |
EP2217697B1 (en) * | 2007-11-08 | 2015-06-10 | Biogen MA Inc. | Use of lingo-4 antagonists in the treatment of conditions involving demyelination |
JP2011527572A (ja) | 2008-07-09 | 2011-11-04 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Lingo抗体または断片を含む組成物 |
WO2010086828A2 (en) * | 2009-02-02 | 2010-08-05 | Rinat Neuroscience Corporation | Agonist anti-trkb monoclonal antibodies |
US9464138B2 (en) * | 2009-04-30 | 2016-10-11 | Ablynx N.V. | Method for the production of domain antibodies |
WO2011103667A1 (en) * | 2010-02-26 | 2011-09-01 | 6452728 Canada Inc. | Agonistic antibodies to trkb receptors and uses thereof |
JP2013523182A (ja) | 2010-04-15 | 2013-06-17 | アボット・ラボラトリーズ | アミロイドベータ結合タンパク質 |
US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
KR20190112175A (ko) | 2010-12-01 | 2019-10-02 | 앨더바이오 홀딩스 엘엘씨 | 항―ngf 조성물 및 그의 용도 |
GB2491106A (en) * | 2011-05-18 | 2012-11-28 | Univ Basel | Antibodies against tropomyosin-related kinase B receptors |
WO2013059740A1 (en) * | 2011-10-21 | 2013-04-25 | Foundation Medicine, Inc. | Novel alk and ntrk1 fusion molecules and uses thereof |
CN102645542A (zh) * | 2012-04-20 | 2012-08-22 | 苏州大学 | Bdnf酶联免疫测定试剂盒 |
US9796780B2 (en) | 2012-05-14 | 2017-10-24 | Biogen Ma Inc. | LINGO-2 antagonists for treatment of conditions involving motor neurons |
WO2014071358A2 (en) | 2012-11-05 | 2014-05-08 | Foundation Medicine, Inc. | Novel ntrk1 fusion molecules and uses thereof |
CN102901815B (zh) * | 2012-11-05 | 2014-10-22 | 武汉远征世纪制药有限公司 | 一种检测TrkB受体816/817位酪氨酸位点活性的ELISA试剂盒及其使用方法 |
US11230589B2 (en) | 2012-11-05 | 2022-01-25 | Foundation Medicine, Inc. | Fusion molecules and uses thereof |
EP3939614A1 (en) | 2013-01-18 | 2022-01-19 | Foundation Medicine, Inc. | Methods of treating cholangiocarcinoma |
WO2015173756A2 (en) | 2014-05-16 | 2015-11-19 | Pfizer Inc. | Bispecific antibodies |
EP3242893A1 (en) | 2015-01-08 | 2017-11-15 | Biogen MA Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
CN108350079B (zh) * | 2015-11-17 | 2021-11-02 | 葛兰素史密斯克莱知识产权发展有限公司 | 用于治疗神经学和其它病症的结合激动剂 |
JP2019517787A (ja) * | 2016-05-03 | 2019-06-27 | ザ スクリプス リサーチ インスティテュート | 神経変性障害の処置のためのTrkBアゴニスト抗体 |
US9914781B1 (en) | 2016-11-08 | 2018-03-13 | Glaxosmithkline Intellectual Property Development Limited | Binding agonist for treatment of neurological and other disorders |
CN114940713B (zh) | 2017-03-15 | 2024-04-30 | 清华大学 | 抗trkb抗体 |
US10793634B2 (en) | 2017-06-09 | 2020-10-06 | Boehringer Ingelheim International Gmbh | Anti-TrkB antibodies |
BR112020006976A2 (pt) * | 2017-11-30 | 2020-10-13 | Regeneron Pharmaceuticals, Inc. | anticorpos monoclonais anti-trkb e métodos de uso |
CN110028585A (zh) * | 2019-02-18 | 2019-07-19 | 广东三九脑科医院 | 兔抗人trk蛋白单克隆抗体制备及其免疫组化用途 |
WO2021102276A1 (en) | 2019-11-22 | 2021-05-27 | Ossianix, Inc. | Bbb-shuttling-vnars conjugated to neurotrophic agonist antibodies to treat neurodegenerative diseases and conditions |
WO2021155141A1 (en) * | 2020-01-30 | 2021-08-05 | Fred Hutchinson Cancer Research Center | Antibody-based compositions for targeting tropomyosin receptor kinase b (trkb) isoforms |
WO2023125485A1 (en) * | 2021-12-28 | 2023-07-06 | 4B Technologies (Beijing) Co., Limited | TrkB ANTIBODY AND APPLICATION THEREOF |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
CA2089661C (en) | 1990-08-29 | 2007-04-03 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5231001A (en) * | 1991-03-14 | 1993-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Trk tyrosine kinase receptor is the physiological receptor for nerve growth factor |
US5811396A (en) * | 1991-03-14 | 1998-09-22 | The United States Of America As Represented By The Department Of Health And Human Services | TRK tyrosine kinase receptor is the physiological receptor for nerve growth factor |
ZA922947B (en) * | 1991-04-23 | 1993-01-27 | Regeneron Pharma | Assay systems for neurotrophin activity |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
US5625121A (en) * | 1993-09-02 | 1997-04-29 | Bristol-Myers Squibb Company | Mice deficient in nerve growth factor receptors encoded by trkB |
US5753225A (en) * | 1993-12-03 | 1998-05-19 | The Regents Of The University Of California | Antibodies that mimic actions of neurotrophins |
US5877016A (en) * | 1994-03-18 | 1999-03-02 | Genentech, Inc. | Human trk receptors and neurotrophic factor inhibitors |
US20040058416A1 (en) * | 1994-03-18 | 2004-03-25 | Presta Leonard G. | Human trk receptors and neurotrophic factor inhibitors |
US5844092A (en) * | 1994-03-18 | 1998-12-01 | Genentech, Inc. | Human TRK receptors and neurotrophic factor inhibitors |
US5601820A (en) * | 1994-07-07 | 1997-02-11 | Children's Hospital Of Philadelphia | Compositions and methods of making and using human full length TRK-B |
US5770577A (en) | 1994-11-14 | 1998-06-23 | Amgen Inc. | BDNF and NT-3 polypeptides selectively linked to polyethylene glycol |
US5688911A (en) * | 1995-05-03 | 1997-11-18 | Schneider; Rainer | Trk neurotrophin binding motifs |
US5880153A (en) * | 1995-11-13 | 1999-03-09 | Spinal Cord Society | Method for upregulation of TRKB and TRKC receptors in central nervous system neurons |
JPH10212241A (ja) | 1996-05-27 | 1998-08-11 | Sumitomo Pharmaceut Co Ltd | Bdnfを安定に含有する製剤 |
SK1499A3 (en) | 1996-07-19 | 1999-08-06 | Amgen Inc | Analogs of cationic proteins |
US6800607B2 (en) | 2000-02-29 | 2004-10-05 | Ltt Bio-Pharma Co., Ltd. | Modified BDNF |
CN100519749C (zh) * | 2000-06-22 | 2009-07-29 | 基因技术股份有限公司 | 抗trk-c拮抗剂的单克隆抗体 |
US7060429B2 (en) * | 2001-02-22 | 2006-06-13 | University Of Maryland, Baltimore | Treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
US20020169154A1 (en) * | 2001-04-04 | 2002-11-14 | Cephalon, Inc. | Novel methods and compositions involving trk tyrosine kinase inhibitors and antineoplastic agents |
US20060148749A1 (en) * | 2002-02-22 | 2006-07-06 | University Of Maryland | Novel treatment of neurodegenerative diseases by altering levels of TrkB isoforms and/or TrkC isoforms |
US20040186044A1 (en) * | 2002-11-06 | 2004-09-23 | Cosgaya Jose Miguel | Modulation of myelination by interaction with P75 and TRK receptors |
-
2006
- 2006-06-05 US US11/446,875 patent/US7750122B2/en not_active Expired - Fee Related
- 2006-06-05 WO PCT/US2006/021878 patent/WO2006133164A2/en active Application Filing
- 2006-06-05 KR KR1020087000331A patent/KR20080032070A/ko not_active Application Discontinuation
- 2006-06-05 BR BRPI0610938-1A patent/BRPI0610938A2/pt not_active IP Right Cessation
- 2006-06-05 AU AU2006255101A patent/AU2006255101A1/en not_active Abandoned
- 2006-06-05 CN CNA2006800287787A patent/CN101273064A/zh active Pending
- 2006-06-05 NZ NZ563941A patent/NZ563941A/en not_active IP Right Cessation
- 2006-06-05 PE PE2006000611A patent/PE20070183A1/es not_active Application Discontinuation
- 2006-06-05 EP EP06772254A patent/EP1891114A2/en not_active Ceased
- 2006-06-05 EP EP10179506A patent/EP2298813A3/en not_active Withdrawn
- 2006-06-05 PA PA20068678401A patent/PA8678401A1/es unknown
- 2006-06-05 JP JP2008515819A patent/JP2008545781A/ja active Pending
- 2006-06-05 MX MX2007015292A patent/MX2007015292A/es active IP Right Grant
- 2006-06-05 GT GT200600240A patent/GT200600240A/es unknown
- 2006-06-05 AR ARP060102341A patent/AR053401A1/es not_active Application Discontinuation
- 2006-06-05 TW TW095119800A patent/TW200722437A/zh unknown
- 2006-06-05 CA CA002610771A patent/CA2610771A1/en not_active Abandoned
- 2006-06-05 RU RU2007144678/13A patent/RU2007144678A/ru unknown
-
2007
- 2007-11-28 IL IL187710A patent/IL187710A0/en unknown
- 2007-11-28 NO NO20076157A patent/NO20076157L/no not_active Application Discontinuation
- 2007-12-03 NI NI200700315A patent/NI200700315A/es unknown
- 2007-12-03 EC EC2007007978A patent/ECSP077978A/es unknown
-
2010
- 2010-06-30 US US12/827,321 patent/US20110150893A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1891114A2 (en) | 2008-02-27 |
NI200700315A (es) | 2008-07-03 |
NZ563941A (en) | 2011-09-30 |
CN101273064A (zh) | 2008-09-24 |
WO2006133164A3 (en) | 2007-03-15 |
TW200722437A (en) | 2007-06-16 |
IL187710A0 (en) | 2008-08-07 |
GT200600240A (es) | 2007-03-14 |
NO20076157L (no) | 2008-02-07 |
AU2006255101A1 (en) | 2006-12-14 |
BRPI0610938A2 (pt) | 2010-08-03 |
MX2007015292A (es) | 2008-02-21 |
PE20070183A1 (es) | 2007-02-26 |
EP2298813A3 (en) | 2012-03-21 |
EP2298813A2 (en) | 2011-03-23 |
JP2008545781A (ja) | 2008-12-18 |
KR20080032070A (ko) | 2008-04-14 |
PA8678401A1 (es) | 2009-05-15 |
US20110150893A1 (en) | 2011-06-23 |
US20070059304A1 (en) | 2007-03-15 |
WO2006133164A2 (en) | 2006-12-14 |
AR053401A1 (es) | 2007-05-02 |
RU2007144678A (ru) | 2009-07-20 |
US7750122B2 (en) | 2010-07-06 |
CA2610771A1 (en) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP077978A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
ECSP13012436A (es) | ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
CO2019012998A2 (es) | Proteínas de unión a antígenos trem2 y usos de estas | |
UA109633C2 (uk) | Антитіло людини проти тканинного фактора | |
AR096895A2 (es) | Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp) | |
NI201200014A (es) | Anticuerpos humanos de alta afinidad para la angiopoyetina - 2 humana | |
GT200900121A (es) | Moleculas de enlace de lingo y uso farmaceutico | |
AR063760A1 (es) | Anticuerpos anti-factor d humanizados y usos de los mismos | |
ECSP055699A (es) | Indazoles, benzotiazoles y benzoisotiazoles, y su preparacion y usos | |
AR059809A1 (es) | Anticuerpos anti-5t4 y sus usos | |
GT201100023A (es) | Anticuerpos neutralizantes del virus anti - influenza a y usos de los mismos | |
ECSP088508A (es) | Antagonistas de neuropilina | |
AR083044A1 (es) | Anticuerpos anti-cd48 y usos de los mismos | |
AR062268A1 (es) | Agentes ligantes direccionados dirigidos a pdgfr-alfa y sus usos | |
EA201100694A1 (ru) | Антитело к cd38 человека и его применение | |
ECSP088613A (es) | Moléculas de anticuerpo que tienen especificidad para la il-6 humana | |
UY32060A (es) | Anticuerpos anti-il-13 obtenidos mediante ingeniería, composiciones , métodos y usos | |
AR071304A1 (es) | Anticuerpos anti cd151 (proteina de membrana de la flia. de las tetraspaninas) utiles para el tratamiento de cancer | |
CO2018000414A2 (es) | Inmunoconjugados de il22 | |
CO2022001194A2 (es) | Moléculas de unión a claudina-6 y usos de las mismas | |
GT201300058A (es) | Composiciones de anticuerpos anti-vegfr-3 | |
AR112770A1 (es) | Anticuerpos anti-ctla-4 y sus usos | |
AR098953A1 (es) | Anticuerpo anti-adam17 (proteína desintegrina y metaloproteinasa-17) y su uso para el tratamiento de cáncer | |
CR9552A (es) | Anticuerpos monoclonales anti-trkb y usos de los mismos | |
AR112975A2 (es) | Anticuerpo humanizado |